Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00COJ
|
|||
| Drug Name |
Inclisiran
|
|||
| Indication | Familial hypercholesterolemia [ICD-11: 5C80.00; ICD-10: E78.0; ICD-9: 272] | Approved | [1] | |
| Hypercholesterolaemia [ICD-11: 5C80.0] | Phase 3 | [2] | ||
| Company |
Novartis/Alnylam
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PCSK9 messenger RNA (PCSK9 mRNA) | Target Info | . | [1] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214012. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.